Pilot prospective evaluation of 18F-alfatide II for detection of skeletal metastases

Theranostics

Volumn 5, Issue 10, 2015, Pages 1115-1121

  Mi, Baoming ^a   Yu, Chunjing ^a   Pan, Donghui ^b   Yang, Min ^b   Wan, Weixing ^a   Niu, Gang ^c   Chen, Xiaoyuan ^c  

^a JIANGNAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Alfatide II; Bone metastasis; Fdg; Pet ct; RGD peptide

Indexed keywords

FLUORINE ALFATIDE II F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ALFATIDE II; CYCLOPEPTIDE;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE MARROW METASTASIS; BONE METASTASIS; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; HUMAN; MALE; MIDDLE AGED; PET SCANNER; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSPECTIVE STUDY; VERY ELDERLY; BONE TUMOR; CHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; METASTASIS; NEOPLASM; PATHOLOGY; SECONDARY;

ADULT; AGED; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PEPTIDES, CYCLIC; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84945955272     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.12938     Document Type: Article

References (36)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. CLin Cancer Res. 2006; 12: 6243s-9s. doi:10.1158/1078-0432.CCR-06-0931.
2. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22: 2942-53. doi:10.1200/JCO. 2004.08.181.
3. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009; 10: 606-14. doi:10.1016/S1470-2045(09)70088-9.
4. Schmidt GP, Schoenberg SO, Reiser MF, Baur-Melnyk A. Whole-body MR imaging of bone marrow. Eur J Radiol. 2005; 55: 33-40. doi:10.1016/j.ejrad.2005.01.019.
5. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 1994; 344: 1265-6.
6. 18F-FDG PET/CT for the detection of skeletal metastases. Acta Radiol. 2014. doi:10.1177/0284185114564438.
7. 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl Med Commun. 2010; 31: 597-603. doi:10.1097/MNM.0b013e328338e909.
8. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004; 231: 305-32. doi:10.1148/radiol.2312021185.
9. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47.
10. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994; 264: 569-71.
11. 18F]galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007; 13: 6610-6.
12. 68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS One. 2012; 7: e37506. doi:10.1371/journal.pone.0037506.
13. Liu D, Wang Z, Jin A, Huang X, Sun X, Wang F, et al. Acetylcholinesterase-catalyzed hydrolysis allows ultrasensitive detection of pathogens with the naked eye. Angew Chem Int Ed Engl. 2013; 52: 14065-9. doi:10.1002/anie.201307952.
14. Zhou Y, Chakraborty S, Liu S. Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics. 2011; 1: 58-82.
15. 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med. 2004; 45: 1776-83.
16. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004; 31: 179-89. doi:10.1016/j.nucmedbio.2003.10.002.
17. 68Ga-RGD positron emission tomography in pediatric cerebral infarct. Mol Imaging. 2013; 12: 213-7.
18. 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: Correlation with histopathology. J Nucl Med. 2015. doi:10.2967/jnumed.114.149021.
19. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008; 49: 879-86.
20. 18F-FDG. J Nucl Med. 2008; 49: 22-9. doi:10.2967/jnumed.107.045864.
21. 18F-Alfatide II and differentiation with tumors. Theranostics. 2014; 4: 546-55. doi:10.7150/thno.8159.
22. 18F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med. 2014; 55: 154-60. doi:10.2967/jnumed.113.122069.
23. Horton MA, Dorey EL, Nesbitt SA, Samanen J, Ali FE, Stadel JM, et al. Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis. J Bone Miner Res. 1993; 8: 239-47. doi:10.1002/jbmr.5650080215.
24. Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, et al. Integrin αvβ3 as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol. 2012; 14: 500-8. doi:10.1007/s11307-011-0512-4.
25. Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ. Targeting the αvβ3 integrin for small-animal PET/CT of osteolytic bone metastases. J Nucl Med. 2009; 50: 1873-80. doi:10.2967/jnumed.109.067140.
26. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006; 12: 6213s-6s. doi:10.1158/1078-0432.CCR-06-1007.
27. 18FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013; 22: 86-91. doi:10.1016/j.suronc.2013.01.002.
28. 64Cu-labeled RGD peptide. J Nucl Med. 2007; 48: 311-8.
29. Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011; 7: 208-18. doi:10.1038/nrendo.2010.227.
30. Glaspy JA, Hawkins R, Hoh CK, Phelps ME. Use of positron emission tomography in oncology. Oncology (Williston Park). 1993; 7: 41-6, 9-50; discussion -2, 5.
31. Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging. 2011; 38: 1469-76. doi:10.1007/s00259-011-1815-z.
32. Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer. 2002; 94: 1522-31.
33. Evangelista L, Panunzio A, Polverosi R, Ferretti A, Chondrogiannis S, Pomerri F, et al. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging. Biomed Pharmacother. 2012; 66: 448-53. doi:10.1016/j.biopha.2012.06.004.
34. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996; 5: 127-35.
35. Hetzel M, Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003; 18: 2206-14. doi:10.1359/jbmr.2003.18.12.2206.
36. Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, et al. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study. PloS One. 2014; 9: e111221. doi:10.1371/journal.pone.0111221.